The global cardiac ablation market size was USD 3.29 Billion in 2022 and is expected to register a revenue CAGR of 14.2% during the forecast period. Growing number of patients suffering from cardiovascular diseases, increasing technological advancements in cardiac ablation equipment, and rising demand for minimally invasive procedures are a few of the key factors expected to drive market revenue growth. Moreover, growing elderly population is increasing demand for cardiac ablation. Various heart conditions such as Atrial fibrillation (AFib) which is a type of irregular heartbeat, can be treated through cardiac ablation, especially when medications and cardioversion do not work.
Living with cardiac arrhythmias is considerable stress for many individuals, disrupting jobs, daily routines, and social activities, with a bad influence on quality of life. According to research, around 12.1 million individuals in the United States are expected to have AFib in 2032. Furthermore, in 2023, AFib was mentioned on 183,321 death certificates as well as was the underlying cause of death in 26,535 of those deaths.
Request a Sample@ https://www.qyresearchmedical.com/sample/119333
Arrhythmia patients who undergo cardiac ablation have symptom alleviation and an increase in quality of life which is one of the major factors boosting the growth of the market. Drug treatment has various side effects or stops working after a while, which is increasing demand for cardiac ablation for longer and curable treatment. On 12 January 2022, Abbott received U.S. Food and Drug Administration clearance for the EnSite X EP System with EnSite Omnipolar technology (OT) which is a new cardiac mapping platform available in the U.S. and across Europe and is designed to assist medical professionals to better treat abnormal heart rhythms. The method, which was developed with the assistance of electrophysiologists from across the globe, generates extremely detailed three-dimensional maps of the heart to assist clinicians in identifying and treating parts of the heart where aberrant rhythms arise.
Emergence of new treatments and integration of advanced technologies is another primary factor driving the revenue growth of cardiac ablation market. Pulsed-field ablation (PFA) is one of the upcoming catheter ablation therapy treatments which is expected to deliver advances in both operation speed and safety. Moreover, hybrid ablation which combines minimally invasive surgical ablation for the outer (epicardial) surface of the heart, with catheter ablation of the inner (endocardial) part of the heart is also expected to provide ample growth opportunities owing to various advantages such as smaller incisions, reduced risk of infections as well as time for recovery. Highest standard surgery for atrial fibrillation is the Cox-maze IV operation which is regarded as the most modern variant of the original maze treatment with a success rate of 80-90%. However, stringent regulations, ongoing reforms in healthcare, and high cost of investments in such treatments are expected to provide some restraints to the growth of the market.
Driver: Growing number of patients suffering from Cardiovascular Diseases (CVDs)
Growth of geriatric population, as well as rapid urbanization causing an increase in air pollution levels, are major factors significantly driving the growth of the market. Cardiovascular disease is considered as a primary cause of global death and almost accounts for 17 million deaths annually. Furthermore, air pollution is among the leading risk factors for such cardiovascular disease. The key factors causing air pollution-induced arrhythmia are regarded to be systemic inflammatory response, cardiac autonomic dysfunction, cardiac structural remodeling, and particle translocation into cardiovascular systems. World Health Organization (WHO) estimates that 17.9 million people died from CVDs in 2023, accounting for 32% of all global fatalities. Heart attacks and strokes were responsible for 85% of these fatalities. Behavioral risk factors such as cigarette use, poor nutrition and obesity, physical inactivity, and excessive alcohol use are leading to the growth of cardiovascular diseases.
Restraint: Involvement of high risk associated with cardiac ablation procedures
Various cardiac ablation risks such as blood vessel damage, worsening arrhythmia, heart stroke, blood clots, narrowing of the veins that carry blood between lungs and heart, and death in rare cases are one of the major factors expected to provide some restraints to the growth of market. According to research, early mortality after atrial fibrillation (AF) ablation affects roughly one in every 200 patients, with the majority of fatalities happening during the 30-day readmission period. Need for permanent pacemaker after such treatment is one of the risks as well. Additionally, patients get exposed to radiation during radiofrequency catheter ablation.
Based on operation, global cardiac ablation market has been segmented cyroablation devices, electrical ablators, radiofrequency ablators, ultrasound ablators, and others. Radiofrequency Ablators (RFA) segment revenue is expected to register a significant growth rate during the forecast period. RFA is a minimally invasive treatment that shrinks the size of tumors, nodules, or other growths in the body. Cost-effectiveness, instant pain relief, better efficiency, and ease-of-use related to radiofrequency ablators are a few of the major factors boosting the growth of the segment. Additionally, RFA has lower risks than an open surgery which is increasing preference for such method. Faster recovery time as well as improved mobility and function are some of the benefits in addition to effective pain relief. Pain alleviation via RFA lasts on average for six months to two years.
Based on application, global cardiac ablation market has been segmented into cardiac rhythm management, open surgery, and others. Cardiac rhythm management segment is further sub-segmented into atrial fibrillation & flutter, cardiac arrhythmia, and tachycardia. Cardiac rhythm management segment is expected to register a significant revenue growth rate over the forecast period owing to various technological advancements. Monitoring devices provide high-efficiency of services and are designed to ensure a better doctor-patient relationship as well as in-depth disease analysis and diagnosis. One of the major advantages is early detection of any irregularity in heart activity as it is necessary for effective treatment. Moreover, integration of cloud-based management helps hospitals better manage databases and streamline operations with more efficiency and better effectiveness. Unhealthy eating habits, excessive alcohol, and smoking consumption with a sedentary lifestyle are major factors increasing number of individuals suffering from Non-Communicable Diseases (NCDs). Surge in NCD is another primary factor boosting the growth of the segment.
Based on end-use, global cardiac ablation market has been segmented into hospitals, cardiac centers, ambulatory surgical centers, and others. Hospitals segment is expected to register a significant revenue growth rate over the forecast period. Growing high-value healthcare investments by various pharmaceutical companies, increasing number of collaborations and rapid technological advancements especially for minimally invasive surgeries are a few of the key factors boosting the revenue growth of the segment. On 7 October 2022, BioSig Technologies, Inc. which is an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP System announced that San Antonio Methodist Hospital which is a leading medical center acquired PURE EP System. PURE EP System is BioSig’s novel digital signal processing technology for arrhythmia care.
Market in North America is expected to account for the largest revenue share in the global cardiac ablation market over the forecast period. Presence of major pharmaceutical and medical equipment companies, increasing number of clinical trials, favorable healthcare reimbursement policies, and significant investments in development of cardiac ablators are some of the key factors boosting the revenue growth of the market in North America. Rise in number of product launches with implantation of various technological advancements is further supporting the growth of the market.
Cardiac Ablation market in Europe is expected to register a steady growth rate over the forecast period owing to growing awareness regarding the availability of advanced treatment procedures and rapid adoption of such treatments. Favorable governmental initiatives, as well as collaborative efforts by companies to provide cost-effective treatment, are also contributing to the growth of the market in the region. On 6 October 2021, Biosense Webster announced the first cases utilizing a radiofrequency balloon ablation catheter completed in September 2021 at sites across Europe using Biosense Webster Heliostart Balloon Ablation Catheter. The Heliostar Balloon Catheter is approved in Europe for catheter-based cardiac electrophysiology (EP) mapping of the atria and cardiac ablation.
Market in Asia Pacific is expected to register a rapid revenue growth rate during the forecast period. Few of the major factors driving the growth of market in Asia Pacific are growing geriatric population, prevalence of cardiovascular diseases, rapid adoption of ablation cardiovascular disease treatment as well as an increasing number of ablation product manufacturers. Countries such as China and India are becoming preferred locations by companies for manufacturing and distribution of cardiac ablation products. According to the World Heart Federation, cardiovascular disease accounts for about one-third of all fatalities in South-East Asia, killing 4 million individuals each year. Air pollution, along with high blood pressure and an unhealthy diet, is a major risk factor for CVD in the region, accounting for almost 17% of all fatalities and 28% of CVD-related deaths.
Competitive landscape of global cardiac ablation market is moderately fragmented with many key companies operating at global and regional levels. Major companies are engaged in research and development initiatives and testing, and entering into alliances to develop and introduce more novel and innovative products and services. Some major companies in the global market report include Abbott, Medtronic, AngioDynamics, Atricure, Inc., Alcon, Boston Scientific Corporation, Olympus Corporation, CONMED, Ethicon, Inc., and BIOTRONIK.
- On 23 August 2022, Medtronic which is known as a global leader in healthcare technology acquired Affera, Inc. Acquisition is expected to expand the company’s existing cardiac ablation portfolio by including its first-ever cardiac mapping and navigation platform which would include a distinct, completely integrated diagnostic, focused pulsed field and radiofrequency ablation solution.
- On 6 September 2022, Biosense Webster, Inc. which is a part of Johnson & Johnson MedTech, launched OCTARAY Mapping Catheter with TRUEref Technology powered by CARTO 3 Version 7 System. The OCTARAYTM Mapping Catheter was designed for mapping cardiac arrhythmias such as atrial fibrillation (AFib).
Segments Covered in the report
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides analysis of market trends in each of sub-segments from 2023 to 2032. For the purpose of this report, has segmented global cardiac ablation market based on product, application, end-use and region:
Cardiac Ablation Market Report Scope
Segments covered By Product Outlook, Application Outlook, End-Use Outlook, Regional Outlook
By Product Outlook
By Application Outlook
Cardiac rhythm management
Atrial fibrillation & flutter
By End-Use Outlook
Ambulatory surgical centers
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://www.qyresearchmedical.com/report/checkout/119333/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: